| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 107 | 2025 | 2418 | 10.930 |
Why?
|
| Antineoplastic Agents, Hormonal | 27 | 2021 | 196 | 5.700 |
Why?
|
| Receptors, Estrogen | 38 | 2025 | 406 | 4.920 |
Why?
|
| Aromatase Inhibitors | 21 | 2022 | 81 | 4.620 |
Why?
|
| Neoadjuvant Therapy | 23 | 2024 | 475 | 2.850 |
Why?
|
| Drug Resistance, Neoplasm | 20 | 2024 | 893 | 2.830 |
Why?
|
| Nitriles | 19 | 2024 | 212 | 2.740 |
Why?
|
| Triazoles | 19 | 2024 | 190 | 2.690 |
Why?
|
| Estrogen Receptor alpha | 11 | 2023 | 154 | 2.650 |
Why?
|
| Biomarkers, Tumor | 27 | 2024 | 1339 | 2.630 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 24 | 2024 | 1998 | 2.340 |
Why?
|
| Triple Negative Breast Neoplasms | 9 | 2024 | 220 | 2.140 |
Why?
|
| Cyclin-Dependent Kinase 4 | 8 | 2025 | 52 | 2.070 |
Why?
|
| Cyclin-Dependent Kinase 6 | 7 | 2025 | 49 | 2.020 |
Why?
|
| Proteogenomics | 7 | 2022 | 12 | 2.000 |
Why?
|
| Mutation | 28 | 2024 | 4093 | 1.910 |
Why?
|
| Antineoplastic Agents | 18 | 2024 | 2219 | 1.630 |
Why?
|
| Ki-67 Antigen | 10 | 2024 | 120 | 1.450 |
Why?
|
| Neoplasms, Hormone-Dependent | 5 | 2016 | 33 | 1.350 |
Why?
|
| Gene Expression Profiling | 17 | 2021 | 1792 | 1.240 |
Why?
|
| Proteomics | 19 | 2022 | 1203 | 1.160 |
Why?
|
| Protein Kinase Inhibitors | 10 | 2025 | 983 | 1.120 |
Why?
|
| Aromatase | 3 | 2016 | 37 | 1.110 |
Why?
|
| Quinolines | 5 | 2022 | 191 | 1.060 |
Why?
|
| Female | 120 | 2025 | 79499 | 1.000 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 6 | 2018 | 111 | 0.970 |
Why?
|
| Genome, Human | 5 | 2016 | 431 | 0.960 |
Why?
|
| Opioid-Related Disorders | 6 | 2025 | 634 | 0.960 |
Why?
|
| Chemotherapy, Adjuvant | 15 | 2020 | 429 | 0.940 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2015 | 92 | 0.930 |
Why?
|
| Xenograft Model Antitumor Assays | 17 | 2025 | 930 | 0.900 |
Why?
|
| Tamoxifen | 10 | 2019 | 193 | 0.890 |
Why?
|
| Humans | 142 | 2025 | 146342 | 0.880 |
Why?
|
| Prognosis | 22 | 2022 | 4351 | 0.840 |
Why?
|
| Neoplasm Recurrence, Local | 13 | 2022 | 1160 | 0.830 |
Why?
|
| Trastuzumab | 5 | 2020 | 119 | 0.830 |
Why?
|
| Postmenopause | 8 | 2024 | 394 | 0.820 |
Why?
|
| Estradiol | 7 | 2016 | 517 | 0.810 |
Why?
|
| Piperazines | 6 | 2025 | 368 | 0.800 |
Why?
|
| Neoplasm Staging | 17 | 2019 | 1488 | 0.730 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2024 | 131 | 0.710 |
Why?
|
| Pyridines | 6 | 2025 | 610 | 0.700 |
Why?
|
| Disease-Free Survival | 13 | 2019 | 778 | 0.680 |
Why?
|
| Circulating Tumor DNA | 2 | 2022 | 50 | 0.670 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2017 | 441 | 0.610 |
Why?
|
| Molecular Sequence Annotation | 4 | 2016 | 110 | 0.610 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 213 | 0.600 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2018 | 970 | 0.590 |
Why?
|
| Estrogens | 3 | 2011 | 364 | 0.590 |
Why?
|
| Heterografts | 7 | 2021 | 143 | 0.570 |
Why?
|
| Cell Line, Tumor | 16 | 2025 | 3545 | 0.570 |
Why?
|
| MutL Proteins | 2 | 2021 | 3 | 0.570 |
Why?
|
| Gene Expression Regulation, Neoplastic | 15 | 2021 | 1432 | 0.570 |
Why?
|
| Genomics | 10 | 2022 | 853 | 0.560 |
Why?
|
| Receptors, Progesterone | 9 | 2018 | 242 | 0.560 |
Why?
|
| Gene Fusion | 1 | 2018 | 31 | 0.550 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2018 | 384 | 0.530 |
Why?
|
| Middle Aged | 48 | 2025 | 36619 | 0.530 |
Why?
|
| HIV Infections | 2 | 2024 | 3215 | 0.520 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2017 | 27 | 0.520 |
Why?
|
| Aged | 43 | 2024 | 26432 | 0.520 |
Why?
|
| Treatment Outcome | 20 | 2021 | 11821 | 0.510 |
Why?
|
| Transcriptome | 9 | 2021 | 1068 | 0.500 |
Why?
|
| Cell Proliferation | 9 | 2025 | 2502 | 0.500 |
Why?
|
| Gene Amplification | 6 | 2017 | 116 | 0.490 |
Why?
|
| Androstadienes | 6 | 2017 | 77 | 0.490 |
Why?
|
| Neoplasms | 10 | 2022 | 2954 | 0.490 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2017 | 59 | 0.480 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2015 | 61 | 0.480 |
Why?
|
| Proteome | 7 | 2020 | 520 | 0.470 |
Why?
|
| Neoplasm Metastasis | 6 | 2018 | 693 | 0.460 |
Why?
|
| Mice | 27 | 2025 | 18297 | 0.430 |
Why?
|
| Selective Estrogen Receptor Modulators | 3 | 2016 | 33 | 0.420 |
Why?
|
| Animals | 34 | 2025 | 38107 | 0.420 |
Why?
|
| Carcinoma, Lobular | 1 | 2014 | 59 | 0.410 |
Why?
|
| Signal Transduction | 17 | 2021 | 5246 | 0.400 |
Why?
|
| Apoptosis | 6 | 2024 | 2439 | 0.400 |
Why?
|
| Survival Analysis | 8 | 2019 | 1378 | 0.390 |
Why?
|
| Adult | 39 | 2025 | 41087 | 0.390 |
Why?
|
| Pharmaceutical Services, Online | 1 | 2012 | 1 | 0.380 |
Why?
|
| Endocrine System | 2 | 2010 | 23 | 0.380 |
Why?
|
| Proportional Hazards Models | 6 | 2019 | 1331 | 0.380 |
Why?
|
| Neurofibromin 1 | 2 | 2025 | 26 | 0.360 |
Why?
|
| Sequence Analysis, DNA | 4 | 2017 | 771 | 0.360 |
Why?
|
| Carcinoma | 2 | 2020 | 225 | 0.360 |
Why?
|
| MCF-7 Cells | 6 | 2021 | 133 | 0.350 |
Why?
|
| Ergocalciferols | 1 | 2011 | 15 | 0.340 |
Why?
|
| E2F Transcription Factors | 1 | 2011 | 65 | 0.340 |
Why?
|
| Prescription Drugs | 1 | 2012 | 110 | 0.330 |
Why?
|
| Bone Density Conservation Agents | 1 | 2011 | 83 | 0.320 |
Why?
|
| RNA, Messenger | 3 | 2021 | 2791 | 0.320 |
Why?
|
| Combined Modality Therapy | 5 | 2017 | 1271 | 0.310 |
Why?
|
| Predictive Value of Tests | 5 | 2017 | 2113 | 0.310 |
Why?
|
| Musculoskeletal Diseases | 1 | 2011 | 95 | 0.300 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2025 | 1763 | 0.300 |
Why?
|
| Mice, Nude | 4 | 2021 | 668 | 0.290 |
Why?
|
| Colonic Neoplasms | 3 | 2019 | 259 | 0.290 |
Why?
|
| Precision Medicine | 1 | 2013 | 462 | 0.280 |
Why?
|
| Mastectomy | 4 | 2015 | 189 | 0.280 |
Why?
|
| Antibodies, Monoclonal | 3 | 2013 | 1512 | 0.280 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2015 | 2488 | 0.280 |
Why?
|
| Protein Kinases | 4 | 2020 | 311 | 0.270 |
Why?
|
| Internet | 1 | 2012 | 660 | 0.270 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 3 | 2017 | 44 | 0.270 |
Why?
|
| Survival Rate | 5 | 2021 | 2092 | 0.270 |
Why?
|
| Oxycodone | 2 | 2025 | 53 | 0.260 |
Why?
|
| Molecular Targeted Therapy | 3 | 2020 | 447 | 0.260 |
Why?
|
| Disease Models, Animal | 8 | 2023 | 4580 | 0.250 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2007 | 64 | 0.240 |
Why?
|
| Paclitaxel | 4 | 2016 | 260 | 0.240 |
Why?
|
| Immunohistochemistry | 6 | 2021 | 1712 | 0.240 |
Why?
|
| Antigens, Neoplasm | 3 | 2020 | 271 | 0.240 |
Why?
|
| Aged, 80 and over | 14 | 2021 | 8391 | 0.240 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 1325 | 0.240 |
Why?
|
| Morpholines | 2 | 2018 | 130 | 0.230 |
Why?
|
| Aminopyridines | 2 | 2018 | 128 | 0.230 |
Why?
|
| Analgesics, Opioid | 4 | 2025 | 1221 | 0.230 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 2 | 2018 | 19 | 0.230 |
Why?
|
| MAP Kinase Kinase 4 | 2 | 2018 | 24 | 0.230 |
Why?
|
| Carboplatin | 2 | 2022 | 168 | 0.220 |
Why?
|
| ROC Curve | 2 | 2017 | 617 | 0.220 |
Why?
|
| Delayed-Action Preparations | 3 | 2025 | 192 | 0.210 |
Why?
|
| Prescription Drug Misuse | 1 | 2025 | 58 | 0.210 |
Why?
|
| Homologous Recombination | 1 | 2024 | 38 | 0.210 |
Why?
|
| Phosphorylation | 8 | 2021 | 1724 | 0.210 |
Why?
|
| Neoplasm Transplantation | 4 | 2017 | 238 | 0.200 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2004 | 59 | 0.200 |
Why?
|
| Needle-Exchange Programs | 1 | 2024 | 16 | 0.200 |
Why?
|
| Healthcare Disparities | 2 | 2025 | 733 | 0.200 |
Why?
|
| Radiation Tolerance | 1 | 2024 | 101 | 0.200 |
Why?
|
| Naloxone | 1 | 2025 | 139 | 0.200 |
Why?
|
| Tramadol | 1 | 2023 | 17 | 0.200 |
Why?
|
| DNA Mutational Analysis | 2 | 2016 | 410 | 0.200 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2020 | 455 | 0.190 |
Why?
|
| Risk Assessment | 7 | 2016 | 3712 | 0.190 |
Why?
|
| Clinical Decision-Making | 2 | 2017 | 365 | 0.190 |
Why?
|
| Harm Reduction | 1 | 2024 | 49 | 0.190 |
Why?
|
| Abscess | 1 | 2024 | 77 | 0.190 |
Why?
|
| Abuse-Deterrent Formulations | 1 | 2023 | 3 | 0.190 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2023 | 27 | 0.190 |
Why?
|
| Drug Compounding | 1 | 2024 | 106 | 0.190 |
Why?
|
| Ovarian Neoplasms | 3 | 2014 | 604 | 0.190 |
Why?
|
| Clinical Trials as Topic | 4 | 2012 | 1064 | 0.190 |
Why?
|
| Peptides | 4 | 2016 | 992 | 0.190 |
Why?
|
| Risk Factors | 8 | 2023 | 10921 | 0.190 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 14 | 0.190 |
Why?
|
| Mass Spectrometry | 5 | 2018 | 729 | 0.190 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2016 | 752 | 0.190 |
Why?
|
| Chemoradiotherapy | 1 | 2024 | 238 | 0.190 |
Why?
|
| Narcotic Antagonists | 1 | 2025 | 210 | 0.180 |
Why?
|
| Incidence | 5 | 2023 | 2936 | 0.180 |
Why?
|
| Computational Biology | 4 | 2015 | 678 | 0.180 |
Why?
|
| Purines | 1 | 2023 | 188 | 0.180 |
Why?
|
| Health Equity | 1 | 2025 | 139 | 0.180 |
Why?
|
| Transfection | 2 | 2018 | 916 | 0.180 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2004 | 315 | 0.180 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2009 | 334 | 0.180 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2020 | 219 | 0.170 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 823 | 0.170 |
Why?
|
| Alleles | 2 | 2016 | 907 | 0.170 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2015 | 166 | 0.170 |
Why?
|
| Maximum Tolerated Dose | 4 | 2016 | 217 | 0.170 |
Why?
|
| Transplantation, Heterologous | 4 | 2015 | 165 | 0.170 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2024 | 429 | 0.170 |
Why?
|
| DNA Mismatch Repair | 1 | 2021 | 54 | 0.160 |
Why?
|
| Transcription Factor AP-1 | 1 | 2020 | 76 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2025 | 1408 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2015 | 992 | 0.160 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2020 | 15 | 0.150 |
Why?
|
| Basal Ganglia Diseases | 1 | 2020 | 10 | 0.150 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 882 | 0.150 |
Why?
|
| Calcium-Binding Proteins | 2 | 2018 | 221 | 0.150 |
Why?
|
| Buprenorphine | 1 | 2023 | 197 | 0.150 |
Why?
|
| Mastectomy, Segmental | 3 | 2015 | 107 | 0.150 |
Why?
|
| Carrier Proteins | 1 | 2023 | 728 | 0.150 |
Why?
|
| Cohort Studies | 3 | 2020 | 6077 | 0.140 |
Why?
|
| Genetic Variation | 2 | 2015 | 996 | 0.140 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2020 | 227 | 0.140 |
Why?
|
| Discoidin Domain Receptor 1 | 1 | 2018 | 3 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2020 | 226 | 0.140 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2018 | 8 | 0.140 |
Why?
|
| tau Proteins | 1 | 2020 | 111 | 0.140 |
Why?
|
| Influenza Vaccines | 1 | 2023 | 544 | 0.140 |
Why?
|
| DNA Repair | 3 | 2020 | 255 | 0.140 |
Why?
|
| DNA Glycosylases | 1 | 2018 | 10 | 0.140 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2025 | 640 | 0.140 |
Why?
|
| Kidney Transplantation | 1 | 2025 | 735 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 200 | 0.140 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2018 | 8 | 0.140 |
Why?
|
| Endonucleases | 1 | 2018 | 35 | 0.140 |
Why?
|
| Imidazoles | 2 | 2010 | 245 | 0.140 |
Why?
|
| NIMA-Related Kinases | 1 | 2018 | 9 | 0.140 |
Why?
|
| Transcriptional Activation | 2 | 2018 | 369 | 0.130 |
Why?
|
| Thymidine Kinase | 1 | 2017 | 14 | 0.130 |
Why?
|
| Time Factors | 5 | 2016 | 7109 | 0.130 |
Why?
|
| Centrifugation, Density Gradient | 1 | 2017 | 37 | 0.130 |
Why?
|
| Phosphoproteins | 3 | 2016 | 320 | 0.130 |
Why?
|
| Drug Synergism | 2 | 2016 | 354 | 0.130 |
Why?
|
| Genomic Instability | 2 | 2020 | 64 | 0.130 |
Why?
|
| Neurodegenerative Diseases | 1 | 2020 | 147 | 0.130 |
Why?
|
| Down-Regulation | 1 | 2020 | 614 | 0.130 |
Why?
|
| Tandem Mass Spectrometry | 6 | 2017 | 576 | 0.130 |
Why?
|
| Endometrial Neoplasms | 1 | 2020 | 205 | 0.130 |
Why?
|
| Adenocarcinoma | 2 | 2015 | 927 | 0.130 |
Why?
|
| Reproducibility of Results | 3 | 2017 | 3416 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2017 | 539 | 0.130 |
Why?
|
| Neoplasm Proteins | 3 | 2017 | 444 | 0.130 |
Why?
|
| Translocation, Genetic | 2 | 2018 | 127 | 0.130 |
Why?
|
| Mitotic Index | 1 | 2017 | 24 | 0.130 |
Why?
|
| RNA, Neoplasm | 2 | 2014 | 76 | 0.120 |
Why?
|
| Spiro Compounds | 1 | 2016 | 18 | 0.120 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 747 | 0.120 |
Why?
|
| Enzyme Activation | 4 | 2017 | 759 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2015 | 2240 | 0.120 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 345 | 0.120 |
Why?
|
| Estrogen Receptor Antagonists | 1 | 2016 | 4 | 0.120 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2016 | 48 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 1107 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 66 | 0.120 |
Why?
|
| Proteolysis | 1 | 2017 | 174 | 0.120 |
Why?
|
| Disease Progression | 3 | 2020 | 2867 | 0.120 |
Why?
|
| Clone Cells | 1 | 2016 | 259 | 0.120 |
Why?
|
| Point Mutation | 2 | 2014 | 232 | 0.120 |
Why?
|
| SEER Program | 2 | 2014 | 233 | 0.120 |
Why?
|
| RNA Interference | 3 | 2018 | 472 | 0.120 |
Why?
|
| Double-Blind Method | 3 | 2016 | 2070 | 0.110 |
Why?
|
| United States | 7 | 2025 | 16136 | 0.110 |
Why?
|
| Genes, Neoplasm | 1 | 2015 | 26 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2016 | 530 | 0.110 |
Why?
|
| Retreatment | 1 | 2015 | 79 | 0.110 |
Why?
|
| Capecitabine | 1 | 2015 | 56 | 0.110 |
Why?
|
| Risk | 2 | 2015 | 920 | 0.110 |
Why?
|
| Exome | 2 | 2017 | 233 | 0.110 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2015 | 116 | 0.110 |
Why?
|
| RNA, Small Interfering | 3 | 2018 | 633 | 0.110 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2016 | 96 | 0.110 |
Why?
|
| Epitopes | 1 | 2017 | 479 | 0.110 |
Why?
|
| Salvage Therapy | 1 | 2016 | 166 | 0.110 |
Why?
|
| Genotype | 3 | 2015 | 1879 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2018 | 429 | 0.110 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 371 | 0.110 |
Why?
|
| Vasomotor System | 1 | 2014 | 47 | 0.110 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 5439 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2018 | 81 | 0.100 |
Why?
|
| Neoplasm Grading | 4 | 2017 | 313 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2019 | 931 | 0.100 |
Why?
|
| Receptor, ErbB-3 | 1 | 2014 | 48 | 0.100 |
Why?
|
| Biomarkers | 3 | 2017 | 4340 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 974 | 0.100 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 1543 | 0.100 |
Why?
|
| Neuregulin-1 | 1 | 2014 | 50 | 0.100 |
Why?
|
| Cell Cycle | 1 | 2017 | 595 | 0.100 |
Why?
|
| Musculoskeletal System | 1 | 2014 | 53 | 0.100 |
Why?
|
| Specimen Handling | 1 | 2016 | 178 | 0.100 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 630 | 0.100 |
Why?
|
| Pilot Projects | 1 | 2020 | 1888 | 0.100 |
Why?
|
| Cancer Survivors | 1 | 2019 | 348 | 0.100 |
Why?
|
| Clonal Evolution | 1 | 2014 | 47 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 4 | 2018 | 504 | 0.100 |
Why?
|
| National Human Genome Research Institute (U.S.) | 1 | 2013 | 1 | 0.100 |
Why?
|
| Cold Ischemia | 1 | 2014 | 39 | 0.100 |
Why?
|
| Asphyxia Neonatorum | 1 | 2013 | 20 | 0.100 |
Why?
|
| Cell Cycle Checkpoints | 3 | 2020 | 97 | 0.100 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2013 | 56 | 0.100 |
Why?
|
| Genes, erbB-2 | 1 | 2013 | 32 | 0.100 |
Why?
|
| Osteoporotic Fractures | 1 | 2014 | 62 | 0.100 |
Why?
|
| Neoplasms, Basal Cell | 1 | 2013 | 4 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 180 | 0.100 |
Why?
|
| Alternative Splicing | 1 | 2015 | 253 | 0.100 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 441 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 597 | 0.090 |
Why?
|
| Central Nervous System Diseases | 1 | 2013 | 73 | 0.090 |
Why?
|
| Rectal Neoplasms | 1 | 2014 | 160 | 0.090 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 272 | 0.090 |
Why?
|
| Chromatography, Liquid | 4 | 2017 | 453 | 0.090 |
Why?
|
| Amino Acid Sequence | 2 | 2015 | 2092 | 0.090 |
Why?
|
| Protein Biosynthesis | 1 | 2015 | 449 | 0.090 |
Why?
|
| Sirolimus | 3 | 2013 | 282 | 0.090 |
Why?
|
| NIH 3T3 Cells | 1 | 2012 | 147 | 0.090 |
Why?
|
| Young Adult | 9 | 2025 | 14330 | 0.090 |
Why?
|
| Indoles | 1 | 2016 | 511 | 0.090 |
Why?
|
| Stroke Volume | 1 | 2016 | 652 | 0.090 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2016 | 391 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2015 | 511 | 0.090 |
Why?
|
| Ventricular Function, Left | 1 | 2016 | 541 | 0.090 |
Why?
|
| Pain | 2 | 2023 | 790 | 0.090 |
Why?
|
| Lymphatic Metastasis | 2 | 2015 | 335 | 0.090 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2012 | 382 | 0.090 |
Why?
|
| Hyperglycemia | 1 | 2016 | 384 | 0.090 |
Why?
|
| Gene Expression | 2 | 2015 | 1463 | 0.090 |
Why?
|
| Osteoporosis | 1 | 2014 | 240 | 0.090 |
Why?
|
| Bone Density | 2 | 2014 | 494 | 0.080 |
Why?
|
| Quinazolines | 1 | 2012 | 267 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2013 | 320 | 0.080 |
Why?
|
| Exons | 1 | 2012 | 361 | 0.080 |
Why?
|
| Poison Control Centers | 2 | 2025 | 85 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2018 | 1468 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2018 | 3647 | 0.080 |
Why?
|
| Parathyroid Hormone | 1 | 2011 | 118 | 0.080 |
Why?
|
| Global Health | 1 | 2013 | 403 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 834 | 0.080 |
Why?
|
| Mice, Inbred NOD | 3 | 2017 | 598 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2021 | 2022 | 0.080 |
Why?
|
| Retinoblastoma Protein | 2 | 2020 | 63 | 0.080 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2010 | 61 | 0.080 |
Why?
|
| Genes, BRCA1 | 1 | 2010 | 45 | 0.080 |
Why?
|
| Diphosphonates | 1 | 2010 | 68 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 628 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 563 | 0.070 |
Why?
|
| Cell Growth Processes | 1 | 2009 | 47 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 776 | 0.070 |
Why?
|
| Male | 12 | 2025 | 73396 | 0.070 |
Why?
|
| Radiopharmaceuticals | 1 | 2009 | 210 | 0.070 |
Why?
|
| Missouri | 2 | 2023 | 66 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2009 | 164 | 0.070 |
Why?
|
| Age Factors | 4 | 2019 | 3347 | 0.070 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 2838 | 0.070 |
Why?
|
| Mice, SCID | 2 | 2021 | 360 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 5899 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 1 | 2009 | 103 | 0.070 |
Why?
|
| Vitamin D | 1 | 2011 | 402 | 0.070 |
Why?
|
| DNA Copy Number Variations | 2 | 2022 | 192 | 0.070 |
Why?
|
| Models, Molecular | 1 | 2012 | 1574 | 0.060 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 343 | 0.060 |
Why?
|
| Health Planning Guidelines | 1 | 2007 | 23 | 0.060 |
Why?
|
| Prospective Studies | 5 | 2019 | 8123 | 0.060 |
Why?
|
| Trinidad and Tobago | 2 | 2018 | 5 | 0.060 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2009 | 215 | 0.060 |
Why?
|
| Perception | 1 | 2010 | 373 | 0.060 |
Why?
|
| Cyclophosphamide | 2 | 2020 | 275 | 0.060 |
Why?
|
| Cell Line | 1 | 2012 | 2814 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2021 | 335 | 0.060 |
Why?
|
| Microsatellite Repeats | 2 | 2020 | 159 | 0.060 |
Why?
|
| Genes, erbB-1 | 1 | 2006 | 21 | 0.060 |
Why?
|
| Genome | 2 | 2021 | 307 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2015 | 2458 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2014 | 702 | 0.060 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 1412 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2008 | 1298 | 0.060 |
Why?
|
| Forecasting | 1 | 2007 | 388 | 0.060 |
Why?
|
| Immunotherapy | 2 | 2021 | 671 | 0.060 |
Why?
|
| Quality of Life | 2 | 2009 | 3200 | 0.060 |
Why?
|
| Cyclin D1 | 1 | 2025 | 64 | 0.060 |
Why?
|
| ErbB Receptors | 2 | 2021 | 636 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2013 | 1730 | 0.050 |
Why?
|
| Calcium | 1 | 2011 | 1181 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2020 | 487 | 0.050 |
Why?
|
| Algorithms | 3 | 2019 | 1849 | 0.050 |
Why?
|
| Phenotype | 1 | 2013 | 3206 | 0.050 |
Why?
|
| Endpoint Determination | 1 | 2005 | 84 | 0.050 |
Why?
|
| Rad51 Recombinase | 1 | 2024 | 15 | 0.050 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2025 | 135 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2005 | 141 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2004 | 84 | 0.050 |
Why?
|
| BRCA2 Protein | 1 | 2024 | 69 | 0.050 |
Why?
|
| BRCA1 Protein | 1 | 2024 | 84 | 0.050 |
Why?
|
| Comparative Effectiveness Research | 1 | 2025 | 171 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2007 | 503 | 0.050 |
Why?
|
| Base Sequence | 1 | 2007 | 2123 | 0.050 |
Why?
|
| Biopsy | 1 | 2007 | 1075 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2006 | 640 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 790 | 0.050 |
Why?
|
| Oxymorphone | 1 | 2023 | 5 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2006 | 423 | 0.050 |
Why?
|
| Phenols | 1 | 2023 | 106 | 0.050 |
Why?
|
| Proteins | 2 | 2021 | 1022 | 0.050 |
Why?
|
| Cisplatin | 1 | 2024 | 347 | 0.040 |
Why?
|
| Recurrence | 2 | 2015 | 1133 | 0.040 |
Why?
|
| Staurosporine | 2 | 2012 | 22 | 0.040 |
Why?
|
| Brazil | 1 | 2022 | 179 | 0.040 |
Why?
|
| Nursing Homes | 1 | 2023 | 171 | 0.040 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2021 | 11 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2016 | 999 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2007 | 1493 | 0.040 |
Why?
|
| Radiotherapy | 2 | 2015 | 209 | 0.040 |
Why?
|
| APOBEC Deaminases | 1 | 2020 | 6 | 0.040 |
Why?
|
| Genes, cdc | 1 | 2020 | 11 | 0.040 |
Why?
|
| Camptothecin | 2 | 2012 | 139 | 0.040 |
Why?
|
| Drug Overdose | 1 | 2025 | 377 | 0.040 |
Why?
|
| Bridged-Ring Compounds | 1 | 2020 | 31 | 0.040 |
Why?
|
| Anthracyclines | 1 | 2020 | 49 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2025 | 553 | 0.040 |
Why?
|
| Feedback, Physiological | 1 | 2020 | 79 | 0.040 |
Why?
|
| Taxoids | 1 | 2020 | 115 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2020 | 196 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 257 | 0.040 |
Why?
|
| Estrogen Antagonists | 1 | 2019 | 37 | 0.040 |
Why?
|
| Acetylation | 1 | 2020 | 262 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2019 | 57 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2020 | 231 | 0.040 |
Why?
|
| Methotrexate | 1 | 2020 | 234 | 0.030 |
Why?
|
| Premenopause | 1 | 2019 | 130 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2019 | 249 | 0.030 |
Why?
|
| Goosecoid Protein | 1 | 2018 | 2 | 0.030 |
Why?
|
| Keratin-19 | 1 | 2018 | 4 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2018 | 18 | 0.030 |
Why?
|
| Biological Mimicry | 1 | 2017 | 2 | 0.030 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2018 | 46 | 0.030 |
Why?
|
| DNA Damage | 1 | 2020 | 439 | 0.030 |
Why?
|
| Cell Survival | 1 | 2021 | 1105 | 0.030 |
Why?
|
| Medicare | 1 | 2023 | 920 | 0.030 |
Why?
|
| Epitope Mapping | 1 | 2017 | 61 | 0.030 |
Why?
|
| RNA, Double-Stranded | 1 | 2017 | 58 | 0.030 |
Why?
|
| Glycolysis | 1 | 2019 | 342 | 0.030 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2017 | 39 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2017 | 123 | 0.030 |
Why?
|
| Web Browser | 1 | 2016 | 12 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2018 | 209 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2016 | 54 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2025 | 1210 | 0.030 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinase 2 | 1 | 2016 | 5 | 0.030 |
Why?
|
| p21-Activated Kinases | 1 | 2016 | 13 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2018 | 328 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2016 | 30 | 0.030 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2016 | 19 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2017 | 180 | 0.030 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2016 | 32 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2017 | 209 | 0.030 |
Why?
|
| Cerebral Cortex | 1 | 2020 | 485 | 0.030 |
Why?
|
| Interferons | 1 | 2017 | 186 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2016 | 127 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2016 | 93 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 508 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 163 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 349 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2015 | 295 | 0.030 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2016 | 121 | 0.030 |
Why?
|
| Viruses | 1 | 2017 | 165 | 0.030 |
Why?
|
| Geography | 1 | 2015 | 187 | 0.030 |
Why?
|
| Molecular Typing | 1 | 2014 | 21 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2015 | 175 | 0.030 |
Why?
|
| Metabolomics | 1 | 2020 | 738 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1707 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 356 | 0.030 |
Why?
|
| Neoplastic Processes | 1 | 2014 | 5 | 0.030 |
Why?
|
| Antibodies, Neoplasm | 1 | 2014 | 34 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2014 | 15 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2014 | 17 | 0.030 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2014 | 14 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 239 | 0.030 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2014 | 46 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 314 | 0.030 |
Why?
|
| Adolescent | 4 | 2019 | 22557 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 319 | 0.030 |
Why?
|
| Pregnancy | 1 | 2007 | 7230 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2017 | 415 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2017 | 430 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2016 | 233 | 0.030 |
Why?
|
| Models, Biological | 1 | 2021 | 1761 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 496 | 0.030 |
Why?
|
| Hot Flashes | 1 | 2014 | 92 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2015 | 368 | 0.030 |
Why?
|
| CpG Islands | 1 | 2014 | 175 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 267 | 0.020 |
Why?
|
| Research Personnel | 1 | 2016 | 190 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2015 | 432 | 0.020 |
Why?
|
| Mass Screening | 1 | 2022 | 1307 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 588 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2020 | 699 | 0.020 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2013 | 24 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 32 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 90 | 0.020 |
Why?
|
| Ribosomal Protein S6 | 1 | 2012 | 18 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 64 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2014 | 496 | 0.020 |
Why?
|
| Gene-Environment Interaction | 1 | 2014 | 190 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2012 | 56 | 0.020 |
Why?
|
| Mortality | 1 | 2015 | 375 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 506 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2015 | 416 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2013 | 224 | 0.020 |
Why?
|
| Morbidity | 1 | 2013 | 319 | 0.020 |
Why?
|
| Washington | 1 | 2013 | 157 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2014 | 334 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2013 | 330 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2015 | 481 | 0.020 |
Why?
|
| Protein Binding | 1 | 2018 | 2244 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2013 | 326 | 0.020 |
Why?
|
| Amino Acids | 1 | 2015 | 515 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 1432 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 287 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 857 | 0.020 |
Why?
|
| Anemia | 1 | 2012 | 190 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 1135 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2014 | 669 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 585 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2022 | 17438 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 2861 | 0.020 |
Why?
|
| Machine Learning | 1 | 2015 | 594 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2010 | 222 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 1327 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2014 | 725 | 0.020 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2009 | 100 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2010 | 310 | 0.020 |
Why?
|
| Age Distribution | 1 | 2009 | 399 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 2107 | 0.020 |
Why?
|
| Docosahexaenoic Acids | 1 | 2008 | 91 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 1077 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 1537 | 0.020 |
Why?
|
| Age of Onset | 1 | 2009 | 558 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1982 | 0.020 |
Why?
|
| Registries | 1 | 2015 | 2400 | 0.010 |
Why?
|
| Social Support | 1 | 2010 | 646 | 0.010 |
Why?
|
| Survivors | 1 | 2009 | 526 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 770 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 1998 | 0.010 |
Why?
|
| Anxiety | 1 | 2010 | 1125 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 3017 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 6073 | 0.010 |
Why?
|
| Child | 1 | 2015 | 22693 | 0.010 |
Why?
|